Patent application number | Description | Published |
20100082339 | Wind Noise Reduction - By monitoring the wind noise in a location in which a cellular telephone is operating and by applying noise reduction and/or cancellation protocols at the appropriate time via analog and/or digital signal processing, it is possible to significantly reduce wind noise entering into a communication system. | 04-01-2010 |
20110004470 | Method for Wind Noise Reduction - A noisy signal is picked up by a microphone, digitized by an Analog to Digital Converter and fed to a processor for analysis and wind noise reduction. Most of noise reduction methods are based on the assumption that the interfering noise is stationary or slowly varying compared with speech. This assumption allows “learning” the characteristics of the noise between speech pauses and, based on a noise estimate, to build different filters that reduce the noise. In the case of wind noise this basic assumption is not valid. Wind noise is highly non-stationary, its power and spectral characteristics vary greatly. Because wind noise is not stationary, regular noise reduction methods cannot be used to reduce wind noise. For reducing wind noise effects in a device, the presence of wind should be detected reliably and then a novel approach presented here must be applied to eliminate the wind noise. | 01-06-2011 |
20110007906 | Wind Noise Classifier - A special purpose machine measures and modulates communication signals that are parsed into frames. Frames of signals modulated and measured to have certain qualities are deemed to be the result of wind noise. Frames of wind noise are cancelled from further use within a communication system. | 01-13-2011 |
20110029308 | Speech & Music Discriminator for Multi-Media Application - The present invention relates to means and methods of classifying speech and music signals in voice communication systems, devices, telephones, and methods, and more specifically, to systems, devices, and methods that automate control when either speech or music is detected over communication links. The present invention provides a novel system and method for monitoring the audio signal, analyze selected audio signal components, compare the results of analysis with a pre-determined threshold value, and classify the audio signal either as speech or music. | 02-03-2011 |
Patent application number | Description | Published |
20090247607 | dsRNA COMPOSITIONS AND METHODS FOR TREATING HPV INFECTION - The invention relates to a double-stranded ribonucleic acid (dsRNA) for treating human papilloma virus (HPV) infection. The dsRNA comprises an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of an HPV Target gene selected from among HPV E1, HPV E6 and the human E6AP gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by HPV infection and the expression of the E6AP gene using the pharmaceutical composition; and methods for inhibiting the expression of the HPV Target genes in a cell. | 10-01-2009 |
20090275638 | Compositions and Methods for Inhibiting Expression of XBP-1 Gene - The invention relates to a double-stranded ribonucleic acid (dsRNA) targeting X-Box Protein 1 (XBP-1), and methods of using the dsRNA to inhibit expression of XBP-1. | 11-05-2009 |
20100010066 | Optimized Methods For Delivery Of DSRNA Targeting The PCSK9 Gene - This invention relates to optimized methods for treating diseases caused by PCSK9 gene expression. | 01-14-2010 |
20100249052 | DSRNA COMPOSITIONS AND METHODS FOR TREATING HPV INFECTIONS - The invention relates to a double-stranded ribonucleic acid (dsRNA) for treating human papilloma virus (HPV) infection. The dsRNA comprises an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of an HPV Target gene selected from the human E6AP gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by HPV infection and the expression of the E6AP gene using the pharmaceutical composition; and methods for inhibiting the expression of the HPV Target genes in a cell. | 09-30-2010 |
20110015252 | LIPID FORMULATED DSRNA TARGETING THE PCSK9 GENE - This invention relates to composition and methods using lipid formulated siRNA targeted to a PCSK9 gene. | 01-20-2011 |
20110152350 | Compositions and Methods for Inhibiting Expression of XBP-1 Gene - The invention relates to a double-stranded ribonucleic acid (dsRNA) targeting X-Box Protein 1 (XBP-1), and methods of using the dsRNA to inhibit expression of XBP-1. | 06-23-2011 |
20110230542 | Compositions and Methods for Inhibiting Expression of the PCSK9 Gene - The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the PCSK9 gene (PCSK9 gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of the PCSK9 gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by PCSK9 gene expression and the expression of the PCSK9 gene using the pharmaceutical composition; and | 09-22-2011 |
20110230546 | dsRNA COMPOSITIONS AND METHODS FOR TREATING HPV INFECTION - The invention relates to a double-stranded ribonucleic acid (dsRNA) for treating human papilloma virus (HPV) infection. The dsRNA comprises an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of an HPV Target gene selected from among HPV E1, HPV E6 and the human E6AP gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by HPV infection and the expression of the E6AP gene using the pharmaceutical composition; and methods for inhibiting the expression of the HPV Target genes in a cell. | 09-22-2011 |
20120016009 | Optimized Methods For Delivery Of DSRNA Targeting The PCSK9 Gene - This invention relates to optimized methods for treating diseases caused by PCSK9 gene expression. | 01-19-2012 |
20120041051 | Compositions And Methods For Inhibiting Expression Of MIG-12 Gene - The invention relates to a double-stranded ribonucleic acid (dsRNA) targeting MIDI interacting G12-like protein (MIG 12) gene, and methods of using the dsRNA to inhibit expression of MIG 12. | 02-16-2012 |
20120244207 | Methods For Increasing Efficacy of Lipid Formulated siRNA - This invention relates to methods for increasing the efficiency of siRNA administrations via pre-administration of an agent that lowers LDL receptor levels. | 09-27-2012 |
20130023580 | Compositions and Methods for Inhibiting Expression of XBP-1 Gene - The invention relates to a double-stranded ribonucleic acid (dsRNA) targeting X-Box Protein 1 (XBP-1), and methods of using the dsRNA to inhibit expression of XBP-1. | 01-24-2013 |
20130035371 | LIPID FORMULATED DSRNA TARGETING THE PCSK9 GENE - This invention relates to composition and methods using lipid formulated siRNA targeted to a PCSK9 gene. | 02-07-2013 |
20130184324 | Dual Targeting siRNA Agents - The invention relates to dual targeting siRNA agents targeting a PCSK9 gene and a second gene, and methods of using dual targeting siRNA agents to inhibit expression of PCSK.9 and to treat PCSK.9 related disorders, e.g., hyperlipidemia. | 07-18-2013 |
20130281511 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE ALAS1 GENE - The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the ALAS1 gene, and methods of using such dsRNA compositions to alter (e.g., inhibit) expression of ALAS1. | 10-24-2013 |
20130331430 | Compositions And Methods For Inhibiting Expression Of The PCSK9 Gene - The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the PCSK9 gene (PCSK9 gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of the PCSK9 gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by PCSK9 gene expression and the expression of the PCSK9 gene using the pharmaceutical composition; and | 12-12-2013 |
20140113957 | Compositions and Methods for Inhibition of Expression of Apolipoprotein C-III (APOC3) Genes - The invention relates to double-stranded ribonucleic acid (dsRNA) targeting an APOC3 gene, and methods of using the dsRNA to inhibit expression of APOC3. | 04-24-2014 |
20140121263 | LIPID FORMULATED DSRNA TARGETING THE PCSK9 GENE - This invention relates to composition and methods using lipid formulated siRNA targeted to a PCSK9 gene. | 05-01-2014 |
20140179768 | ANGIOPOIETIN-LIKE 3 (ANGPTL3) iRNA COMPOSITIONS AND METHODS OF USE THEREOF - The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the ANGPTL3 gene, as well as methods of inhibiting expression of ANGPTL3 and methods of treating subjects having a disorder of lipid metabolism, such as hyperlipidemia or hypertriglyceridemia, using such dsRNA compositions. | 06-26-2014 |
20140256791 | Compositions and Methods for Inhibiting Expression of XBP-1 Gene - The invention relates to a double-stranded ribonucleic acid (dsRNA) targeting X-Box Protein 1 (XBP-1), and methods of using the dsRNA to inhibit expression of XBP-1. | 09-11-2014 |
20140350075 | Compositions and Methods for Inhibiting Expression of the PCSK9 Gene - The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the PCSK9 gene (PCSK9 gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of the PCSK9 gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier and method for treating diseases caused by PCSK9 gene expression. | 11-27-2014 |
Patent application number | Description | Published |
20100222417 | Compostions and methods for enhancing oligonucleotide delivery across and into epithelial tissues - The present invention relates to the delivery of oligonucleotide across and into epithelial tissues by conjugating the oligonucleotide with a lipophile and/or coadministering with a penetration enhancer. In particular, the present invention provides a composition comprising a conjugated siRNA, which are advantageous for the in vivo delivery of nucleic acids across and into epithelial tissue. Additionally, the present invention provides methods of improving delivery of oligonucleotides across the epithelial tissues with the aid of a mechanical enhancer. | 09-02-2010 |
20110218334 | PHOSPHOROTHIOATE OLIGONUCLEOTIDES AND NON-NUCLEOSIDIC PHOSPHOROTHIOATES AS DELIVERY AGENTS FOR iRNA AGENTS - The invention relates to use of single-stranded phosphorothioate oligonucleotides or non-nucleosidic phosphrothiaote as vehicles or carriers to modulate the biodistribution of iRNA agents. | 09-08-2011 |
20130123332 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF MYLIP/IDOL GENE - The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the Mylip/Idol gene, and methods of using such dsRNA compositions to inhibit expression of Mylip/Idol. | 05-16-2013 |
20130289094 | Compositions and Methods for Inhibition of PCSK9 Genes - The invention relates to siRNAs targeting a PCSK9 gene, and methods of using siRNAs to inhibit expression of PC-SK9 and to treat PCSK9 related disorders, e.g., hyperlipidemia. | 10-31-2013 |
20130317080 | MODIFIED iRNA AGENTS - The present invention provides effective motifs for RNA agents conjugated to at least one ligand, which are advantageous for the in vivo delivery of iRNA duplex agents. Additionally, the present invention provides methods of making these compositions, as well as methods of introducing these iRNA duplex agents into cells using these compositions, e.g., for the treatment of various disease conditions. | 11-28-2013 |